Travel Vaccine Sales Drive Bavarian Nordic Growth
Suppliers to travel-health and public-preparedness buyers should expect margins to ease in the fourth quarter as planned investment rises.
Updated on Nov. 13, 2026 in Economic Indicators
Live Poll
Do you think access to routine vaccines is getting better or worse where you live?
Danish vaccine maker Bavarian Nordic reported third-quarter 2026 revenue of DKK 1,805 million, roughly flat against DKK 1,795 million a year earlier, and kept its full-year 2026 revenue guidance of about DKK 6,100 million. The company's travel-health vaccines drove the quarter, which matters for operators in travel health, public-health procurement and specialty pharmaceutical distribution.
Why it matters
Growth came from travel vaccines, where RabAvert/Rabipur and the newer Vimkunya are gaining share, while public-preparedness revenue carried less weight. Management's margin outlook for the year reflects planned fourth-quarter spending and revenue timing, so the quarter's strong margin is not expected to persist through year-end.
Third-quarter revenue of DKK 1,805 million was essentially flat year over year against DKK 1,795 million, while Travel Health grew 22% to DKK 1,144 million and Vimkunya sales rose 146% to DKK 73 million. Third-quarter EBITDA reached DKK 621 million, a 34.4% margin, and nine-month revenue of DKK 4,897 million was up 2%.
The players
Bavarian Nordic A/S
A Copenhagen-based vaccine developer and manufacturer whose travel-health and public-preparedness products serve government and travel markets.
Tarja Stenvall
Bavarian Nordic's newly appointed chief executive, who took over the role in October 2026.
Henrik Juuel
Bavarian Nordic's chief financial officer, who is scheduled to step down in April 2027.
The details
Travel Health growth came from continued strong sales of RabAvert/Rabipur and the continued launch of Vimkunya, while public-preparedness revenue of DKK 606 million supplied the rest of the quarter's revenue. The third-quarter EBITDA margin reflected a strong topline combined with a more favorable product and market mix. Gross margin in the quarter was 51.9%. The company expects its full-year EBITDA margin to decline because revenue is phased into the fourth quarter alongside higher investment levels.
Timeline
August 2026: The European Commission approved use of the MVA-BN mpox and smallpox vaccine for children aged 2 to under 12.
September 2026: Tarja Stenvall was appointed new CEO, effective October 15, 2026.
October 8, 2026: The company issued upgraded full-year 2026 guidance, which it maintained in this report.
April 2027: CFO Henrik Juuel is scheduled to step down.
Market Landscape
The August pediatric approval extends a vaccine whose commercial relevance rose sharply during the 2022 mpox outbreak, when MVA-BN was deployed under emergency authorization for adults. Travel vaccines and public-preparedness contracts now make up the company's revenue mix, which is the segment where its competitive position is being tested.
Operators in travel health and public-health procurement should watch whether RabAvert/Rabipur and Vimkunya keep their growth rates, since these products drove the quarter. Procurement and finance teams should note that the company expects a lower full-year EBITDA margin than the quarter's 34.4%, which signals rising fourth-quarter costs.
The takeaway
The key operating signal is that travel-health vaccine sales are carrying the company's growth while public-preparedness revenue carries less. Operators tracking this segment should watch the fourth-quarter results for whether the expected margin decline materializes.
What happens next
Bavarian Nordic's CFO Henrik Juuel is scheduled to step down in April 2027, and the company has initiated a search for his successor.
Further reading
For the broader measures used to read company results like these against the economy, see Economic Indicators.
Live Poll
Do you think access to routine vaccines is getting better or worse where you live?
